King Hussein Cancer Center Partners with ReMedi Health Solutions to Advance AI Readiness and Transform Cancer Care
King Hussein Cancer Center (KHCC), one of the Middle East’s leading oncology institutions, has launched a significant artificial intelligence (AI) readiness initiative by selecting ReMedi Health Solutions as the U.S. prime contractor for the project. Supported through a Technical Assistance grant awarded by the U.S. Trade and Development Agency (USTDA) to the King Hussein Cancer Foundation (KHCF), the initiative is designed to strengthen KHCC’s AI capabilities while laying the foundation for responsible, scalable AI adoption across both clinical and administrative operations.
The project represents a major step in KHCC’s long-term digital transformation strategy and supports the organization’s Office of Artificial Intelligence and Information Innovations. Rather than focusing solely on deploying AI tools, the initiative emphasizes building the governance, infrastructure, workflows, and organizational readiness necessary to integrate artificial intelligence safely and effectively into everyday healthcare delivery.
As healthcare providers around the world increasingly explore AI-powered technologies to improve diagnosis, patient care, research, and operational efficiency, KHCC aims to establish a framework that allows these innovations to deliver measurable clinical value while maintaining patient safety and regulatory compliance.
Building a Foundation for Artificial Intelligence in Healthcare
Artificial intelligence continues to reshape healthcare by enabling faster data analysis, improving clinical decision support, streamlining administrative tasks, and assisting physicians in identifying diseases earlier than traditional methods alone.
However, successful AI implementation requires much more than purchasing software.
Healthcare organizations must establish governance structures, develop implementation strategies, integrate AI into existing electronic health record systems, ensure high-quality clinical data, address privacy and cybersecurity concerns, and prepare clinicians to use new technologies confidently.
The initiative led by ReMedi Health Solutions focuses specifically on these foundational requirements.
Through the USTDA-funded technical assistance program, KHCC will strengthen its organizational AI governance, improve institutional readiness, and develop practical implementation plans that support sustainable adoption across multiple departments.
Rather than introducing isolated AI solutions, the project seeks to establish a long-term roadmap that aligns technology investments with clinical priorities and operational goals.
Three Initial AI Pilot Programs
A central component of the engagement involves launching three targeted AI pilot projects designed to demonstrate practical applications of artificial intelligence within cancer care.
The pilots will focus on:
- Business intelligence and operational analytics
- Breast cancer diagnostics
- Clinical trials screening
Each initiative addresses a different aspect of healthcare delivery while providing valuable insights into how AI can improve efficiency, decision-making, and patient outcomes.
Enhancing Business Intelligence
Healthcare organizations generate enormous volumes of operational and clinical data every day.
AI-powered business intelligence tools can analyze this information to identify operational bottlenecks, improve resource allocation, monitor performance indicators, and provide leadership with actionable insights for strategic planning.
For KHCC, enhanced business intelligence could improve hospital operations, optimize staffing, monitor patient flow, and support data-driven management decisions.
Improved operational visibility also enables healthcare leaders to respond more quickly to changing patient demands while maintaining high standards of care.
Improving Breast Cancer Diagnostics
Breast cancer remains one of the most common cancers affecting women worldwide, and early diagnosis plays a critical role in improving treatment outcomes.
Artificial intelligence has demonstrated growing potential in assisting radiologists and oncologists by identifying subtle imaging patterns that may indicate early-stage disease.
The breast cancer diagnostics pilot will explore how AI can support physicians during diagnostic workflows, potentially improving detection accuracy while reducing interpretation time.
Importantly, the technology is intended to support—not replace—clinical expertise by providing additional decision-support capabilities during patient evaluation.
Accelerating Clinical Trial Screening
Clinical trials remain essential for advancing cancer treatment, yet identifying eligible participants often requires reviewing extensive patient records against detailed eligibility criteria.
Artificial intelligence can significantly reduce the time required for patient screening by analyzing electronic health records, identifying potential candidates, and matching individuals with appropriate research studies.
The clinical trials screening pilot aims to streamline this process, helping researchers enroll qualified participants more efficiently while expanding patient access to innovative therapies.
Faster trial enrollment also contributes to more rapid medical research and improved development of future cancer treatments.
Identifying Future AI Technology Partners
In addition to supporting the initial pilot programs, the engagement includes evaluating potential U.S. technology providers that could supply additional artificial intelligence solutions for KHCC in the future.
ReMedi Health Solutions will help identify companies offering technologies that align with KHCC’s long-term digital strategy.
These evaluations will consider factors including:
- Clinical effectiveness
- Integration capabilities
- Operational scalability
- Regulatory compliance
- Long-term sustainability
By conducting structured vendor assessments, KHCC aims to ensure future AI investments align with both clinical objectives and institutional infrastructure.
This approach minimizes implementation risks while supporting thoughtful expansion of AI capabilities over time.
Supporting Better Patient Care
Ultimately, the initiative seeks to improve multiple aspects of healthcare delivery.
Artificial intelligence has the potential to support:
- Earlier disease detection
- More informed clinical decision-making
- Personalized treatment planning
- Improved operational efficiency
- Better resource utilization
- Enhanced patient experiences
- Stronger research capabilities
Rather than replacing physicians or healthcare professionals, AI is increasingly viewed as a tool that enhances clinical decision-making by providing timely access to relevant information and analytical insights.
This collaborative approach allows clinicians to devote more time to direct patient care while reducing administrative burdens.
Leadership Perspective from KHCC
Dr. Asem Mansour, Chief Executive Officer of King Hussein Cancer Center, emphasized the broader impact AI could have across the institution.
According to Dr. Mansour, expanding the use of artificial intelligence has the potential to reduce administrative workloads, strengthen clinical decision support, enable more personalized medicine, improve patient experiences, and enhance KHCC’s research capabilities.
These goals reflect the growing recognition that AI can contribute not only to patient diagnosis but also to hospital operations, physician productivity, and scientific discovery.
As one of the region’s leading oncology institutions, KHCC views AI as an important component of its long-term strategy for delivering world-class cancer care.
A Leading Regional Cancer Center
King Hussein Cancer Center occupies a unique position within Jordan’s healthcare system.
The institution treats approximately 60 percent of all cancer cases diagnosed throughout Jordan, making it one of the country’s most important healthcare providers.
Beyond serving Jordanian patients, KHCC also functions as a regional referral center, providing advanced oncology services for patients from across the Middle East.
Its concentration of cancer specialists, researchers, and advanced treatment programs creates an ideal environment for evaluating emerging healthcare technologies, including artificial intelligence.
The large and diverse patient population also provides valuable opportunities for developing AI models that address complex oncology workflows.
Working Within an Established Electronic Health Record System
Unlike many AI initiatives designed for newly built cloud-based healthcare platforms, KHCC operates within Jordan’s national Hakeem electronic health record (EHR) ecosystem.
The Hakeem platform is based on the well-established VistA architecture and supports active patient care across the country’s healthcare system.
Many commercial AI products assume organizations already possess cloud-native healthcare data environments.
In reality, many hospitals continue to rely on mature enterprise EHR systems that require specialized integration approaches.
Recognizing this reality, ReMedi Health Solutions has tailored its implementation strategy around the healthcare infrastructure clinicians already use.
Rather than requiring hospitals to replace existing workflows, the initiative focuses on embedding AI directly into established clinical processes.
This practical approach helps encourage physician adoption while minimizing disruption to patient care.
ReMedi’s Clinical Approach to AI
Dr. Sonny Hyare, Chief Executive Officer of ReMedi Health Solutions, emphasized that successful AI implementation depends on understanding healthcare operations rather than simply deploying technology.
According to Hyare, artificial intelligence delivers value only when it supports the natural collaboration between clinicians and operational teams.
He noted that KHCC combines a clear organizational vision with a highly complex healthcare environment, making clinically guided implementation especially important.
ReMedi’s objective is to help the organization move beyond interest in AI toward sustainable operational readiness that functions effectively at the point of care.
This philosophy reflects a growing industry trend that prioritizes workflow integration, clinician engagement, and governance alongside technological innovation.
Collaboration Across Multiple Organizations
The AI readiness initiative represents a collaborative effort involving multiple organizations with complementary expertise.
The King Hussein Cancer Foundation and King Hussein Cancer Center provide clinical leadership, institutional oversight, and strategic direction for the initiative.
Funding is provided by the U.S. Trade and Development Agency, whose Technical Assistance grant supports digital healthcare modernization while strengthening international partnerships.
The project also aligns with broader priorities established through the U.S. Partnership for Global Infrastructure and Investment as well as Jordan’s Artificial Intelligence Strategy and Implementation Plan 2023–2027.
This alignment ensures the initiative contributes to both institutional objectives and national healthcare innovation strategies.
Electronic Health Solutions Supports System Integration
An important technical component of the project comes from Electronic Health Solutions (EHS), the national digital health organization responsible for Jordan’s Hakeem electronic health record system.
EHS will provide the EHR interfaces and system integration required for the three AI pilot programs.
Because AI systems rely heavily on accurate, accessible clinical data, seamless integration with electronic health records is essential.
By leveraging Hakeem’s existing infrastructure, the project seeks to deliver AI capabilities within clinicians’ normal workflows rather than requiring separate applications or duplicate documentation.
Folio3 Powers AI Engineering
Supporting the technical implementation is Folio3, ReMedi Health Solutions’ technology partner.
Folio3 contributes specialized expertise in AI engineering, healthcare software development, electronic health record integration, and clinical data engineering.
Its role involves developing the underlying AI capabilities that support the three pilot initiatives while ensuring interoperability with existing healthcare systems.
By embedding artificial intelligence into routine clinical workflows, Folio3 aims to transform the pilot projects from experimental concepts into practical decision-support tools that physicians and care teams can use in their daily practice.
Positioning KHCC for the Future of AI-Driven Healthcare
As healthcare organizations worldwide continue exploring artificial intelligence, successful implementation increasingly depends on organizational readiness rather than technology alone.
King Hussein Cancer Center’s partnership with ReMedi Health Solutions demonstrates a comprehensive approach that combines governance, clinical leadership, infrastructure planning, workflow integration, and targeted pilot programs before broader deployment.
By strengthening AI readiness today, KHCC is positioning itself to adopt future innovations responsibly while continuing to improve cancer diagnosis, treatment, research, and operational performance.
With support from USTDA, collaboration among leading healthcare organizations, and expertise from technology partners specializing in clinical AI, the initiative represents an important milestone in advancing AI-enabled oncology care across Jordan and the wider Middle East.
Source link: https://www.businesswire.com/
